Prexa Pharmaceuticals
Boston
About Prexa Pharmaceuticals
Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinson’s disease. Prexa’s proprietary compound portfolio consists of highly differentiated reuptake inhibitors with unique dopamine-preferring neurotransmitter selectivity profiles. Prexa’s lead compound, PRX-12251, is a triple reuptake inhibitor that blocks dopamine, norepinephrine and serotonin transporters. PRX-12251 is entering IND-enabling studies. Prexa’s mono and dual reuptake inhibitors are targeted for partnerships with leading biotechnology and pharmaceutical companies.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $10.2M
- Funding stage: Early Stage Venture
- Last round: Series B (May 2011)
- Website: prexainc.com
- Phone: +1 617 780 1443
Industries & Categories
Biotechnology, Health Care, Health Diagnostics
Canonical: https://fsome.com/organization/prexa-pharmaceuticals-1156559 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.